Mammography Performance Is Not Improved With Computer-Aided Detection Technology

Share this content:
Mammography Performance Is Not Improved With Computer-Aided Detection Technology
Mammography Performance Is Not Improved With Computer-Aided Detection Technology

Computer-aided detection (CAD) in screening mammography is not associated with improved diagnostic accuracy, according to an analysis of results from a large Breast Cancer Surveillance Consortium database of digital screening mammograms. The findings were published by JAMA Internal Medicine (2015; doi:10.1001/jamainternmed.2015.5231).

CAD for mammography is intended to help radiologists identify subtle cancers that might otherwise be missed. The US Food and Drug Administration approved CAD for mammography in 1998 and the Centers for Medicare and Medicaid Services (CMS) increased reimbursement for CAD in 2002. Measuring the true impact of CAD on the accuracy of mammographic interpretation has been challenging.

Constance D. Lehman, MD, PhD, of the Massachusetts General Hospital in Boston and coauthors measured the performance of digital screening mammography with and without CAD in US community practice. The authors included more than 625,000 mammograms interpreted by 271 radiologists with CAD (n=495,818) or without (n=129,807) from 2003 through 2009 among 323,973 women. Linkages with tumor registries identified 3,159 breast cancers in the 323,973 women within 1 year of the screening.

The authors analyzed mammography performance based on sensitivity (the ability of a test to correctly identify those who do have the disease), specificity (the ability of a test to correctly identify those who do not have the disease) and cancer detection rates per 1,000 women.

Screening performance with CAD was not associated with improvement based on the metrics the authors assessed. Sensitivity was 85.3% with CAD and 87.3% without CAD, while specificity was 91.6% with CAD and 91.4% without CAD.

The authors also found no difference in the overall cancer detection rate (4.1 cancers per 1,000 women screened with and without CAD) or in the invasive cancer detection rate (2.9 vs. 3.0 cancers per 1,000 women screened with CAD or without, respectively), according to the results. Although the detection rate for ductal carcinoma in situ (DCIS) was slightly higher in patients whose mammograms were assessed with CAD compared with those without (1.2 vs. 0.9 cancers per 1,000 women), finding more low-grade DCIS may offer no improved outcomes for women in screening programs.

In subset analyses among 107 radiologists who interpreted mammograms both with and without CAD, performance was not improved with CAD and CAD was associated with decreased sensitivity.

“In the era of Choosing Wisely and clear commitments to support technology that brings added value to the patient experience, while aggressively reducing waste and containing costs, CAD is a technology that does not seem to warrant added compensation beyond coverage of the mammographic examination. The results of our comprehensive study lend no support for continued reimbursement for CAD as a method to increase mammography performance or improve patient outcomes,” the authors concluded.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs